BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 15508092)

  • 1. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.
    Wiesner RH; Freeman RB; Mulligan DC
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S261-7. PubMed ID: 15508092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model for end-stage liver disease: did the new liver allocation policy affect waiting list mortality?
    Austin MT; Poulose BK; Ray WA; Arbogast PG; Feurer ID; Pinson CW
    Arch Surg; 2007 Nov; 142(11):1079-85. PubMed ID: 18025337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.
    Pomfret EA; Washburn K; Wald C; Nalesnik MA; Douglas D; Russo M; Roberts J; Reich DJ; Schwartz ME; Mieles L; Lee FT; Florman S; Yao F; Harper A; Edwards E; Freeman R; Lake J
    Liver Transpl; 2010 Mar; 16(3):262-78. PubMed ID: 20209641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
    J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY; Bass NM; Ascher NL; Roberts JP
    Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement?
    Roayaie K; Feng S
    Liver Transpl; 2007 Nov; 13(11 Suppl 2):S36-43. PubMed ID: 17969067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation in the MELD era: a single-center experience.
    Sachdev M; Hernandez JL; Sharma P; Douglas DD; Byrne T; Harrison ME; Mulligan D; Moss A; Reddy K; Vargas HE; Rakela J; Balan V
    Dig Dis Sci; 2006 Jun; 51(6):1070-8. PubMed ID: 16865573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
    Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
    J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplant recipient selection: MELD vs. clinical judgment.
    Fink MA; Angus PW; Gow PJ; Berry SR; Wang BZ; Muralidharan V; Christophi C; Jones RM
    Liver Transpl; 2005 Jun; 11(6):621-6. PubMed ID: 15915491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation.
    Ferre-Aracil C; Lledó JL; Aguilera L; Garcia-Paredes A; Rodríguez-Santiago E; Graus J; García-González M; Nuño J; López-Buenadicha A; López-Hervás P; Rodríguez-Gandía M; Gea F; Albillos A
    Dig Liver Dis; 2018 Dec; 50(12):1345-1350. PubMed ID: 29807872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation.
    Volk ML; Lok AS; Pelletier SJ; Ubel PA; Hayward RA
    Gastroenterology; 2008 Nov; 135(5):1568-74. PubMed ID: 19009713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the allocation system for deceased donor liver transplantation.
    Coombes JM; Trotter JF
    Clin Med Res; 2005 May; 3(2):87-92. PubMed ID: 16012126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.